Loading...
Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF Study (Reduction of events by darbepoetin alfa in heart failure): Clinical and prognostic associations
Principal Supervisor
Co-Supervisor
Degree Name
Abstract
Background:
A poor response to erythropoiesis-stimulating agents such as darbepoetin alfa has been associated with adverse outcomes in patients with diabetes mellitus, chronic kidney disease, and anemia; whether this is also true in heart failure is unclear.
Methods and Results:
We performed a post hoc analysis of the RED-HF trial (Reduction of Events by Darbepoetin Alfa in Heart Failure), in which 1008 patients with systolic heart failure and anemia (hemoglobin level, 9.0–12.0 g/dL) were randomized to darbepoetin alfa. We examined the relationship between the hematopoietic response to darbepoetin alfa and the incidence of all-cause death or first heart failure hospitalization during a follow-up of 28 months. For the purposes of the present study, patients in the lowest quartile of hemoglobin change after 4 weeks were considered nonresponders. The median initial hemoglobin change in nonresponders (n=252) was −0.25 g/dL and +1.00 g/dL in the remainder of patients (n=756). Worse renal function, lower sodium levels, and less use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were independently associated with nonresponse. Although a low endogenous erythropoietin level helped to differentiate responders from nonresponders, its predictive value in a multivariable model was poor (C statistic=0.69). Nonresponders had a higher rate of all-cause death or first heart failure hospitalization (hazard ratio, 1.25; 95% confidence interval, 1.02–1.54) and a higher risk of all-cause mortality (hazard ratio, 1.30; 95% confidence interval, 1.04–1.63) than responders.
Conclusions:
A poor response to darbepoetin alfa was associated with worse outcomes in heart failure patients with anemia. Patients with a poor response were difficult to identify using clinical and biochemical biomarkers.
Clinical Trial Registration:
URL: https://www.clinicaltrials.gov. Unique identifier: NCT00358215.
Keywords
darbepoetin alfa, heart failure, erythropoietin, anemia
Publication Date
2018
Type
Journal article
Published In
Circulation: Heart Failure
Volume
11
Issue
2
Article Number
Start page
End page
Page Range
1-5
ACU Organisational Area
Collections
ACU Research Bank Link
Related
Open Access Status
File Access
Controlled
